Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Date
2019
Author
ten Berg, Jurrien M.
Ongen, Zeki
Kleine, Eva
Bhatt, Deepak L.
Cannon, Christopher P.
Hohnloser, Stefan H.
Steg, Philippe Gabriel
Oldgren, Jonas
Nickenig, Georg
Kiss, Robert G.
Navarro Estrada, Jose L.
Ophuis, Ton Oude
Lip, Gregory Y. H.
Nordaby, Matias
Metadata
Show full item record
Abstract
OBJECTIVES The study sought to evaluate the effect of dabigatran dual therapy versus warfarin triple therapy across categories of renal function in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.
URI
http://hdl.handle.net/20.500.12627/157651
https://doi.org/10.1016/j.jcin.2019.05.050
Collections